<DOC>
	<DOCNO>NCT00005827</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Randomized phase I trial determine effectiveness genistein treat patient stage II , stage III , stage IV prostate cancer .</brief_summary>
	<brief_title>Genistein Treating Patients With Stage II , Stage III , Stage IV Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety pharmacokinetics genistein patient stage II , III , IV prostate cancer . OUTLINE : This randomize , double blind , placebo control study . Patients randomize one two treatment arm . Arm I : Patients receive oral genistein twice daily . Arm II : Patients receive oral placebo twice daily . Treatment continue 3 month absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 24 patient accrue study within 6 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Genistein</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage B , C , D adenocarcinoma prostate amenable surgery PATIENT CHARACTERISTICS : Age : 40 Performance status : ECOG 02 Life expectancy : At least 6 month Hematopoietic : WBC least 3,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL Transaminases le 4 time upper limit normal Renal : Creatinine le 2.0 mg/dL Cardiovascular : No New York Heart Association class III IV heart disease Other : No significant abnormality internal organ , neurologic status , biochemical level No history seizures No concurrent serious illness No acute infection require antibiotic therapy except chronic urinary tract infection No prior concurrent malignancy within past 2 year except nonmelanoma carcinoma skin No history substance abuse addiction No alcohol intake great 2 drinks/day 14 drinks/week No diet contain 20 mg genistein/day No known soy intolerance No prior breast cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : At least 3 month since prior hormonal therapy OR No concurrent estrogen Other concurrent hormonal therapy allow stable regimen 3 month Radiotherapy : At least 4 week since prior radiotherapy recover Surgery : See Disease Characteristics At least 3 week since prior surgery recover Other : At least 6 week since prior antibiotic No concurrent genotoxicity therapy</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>